SAB Biotherapeutics (SABS) has issued an update.
SAB Biotherapeutics, Inc. has entered into new executive employment agreements with Eddie J. Sullivan, its President, and Christoph Bausch, its COO, both effective from January 1, 2024. Sullivan’s agreement includes a $485,000 annual base salary and up to a 50% bonus potential, while Bausch’s includes a $425,000 salary and up to a 40% bonus potential. Both executives are eligible for company benefits and will adhere to standard non-competition and non-solicitation clauses. These agreements replace their previous contracts without any familial conflicts of interest reported within the company’s leadership.
For a thorough assessment of SABS stock, go to TipRanks’ Stock Analysis page.
